Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3‐year single‐centre experience

Abstract

Adalimumab therapy may be effective in the long term in both luminal and fistulizing Crohn's disease in infliximab-failure patients, half of patients maintaining clinical response and potentially avoiding major abdominal surgery in 80% of cases.